Simon Husby

University of Copenhagen

Denmark

Research Interests

Explore related searches

Professors in Cancer Biology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Collaborators (5)

Judit Meszaros Joergensen

Aarhus University

DENMARK

View details

Sara Ek

SWEDEN

View details

Michael Boe Møller

Syddansk Universitet Det Sundhedsvidenskabelige Fakultet

DENMARK

View details

Thomas Stauffer Larsen

Odense University Hospital

DENMARK

View details

Martin Hutchings

Professor

University of Copenhagen

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Simon Husby

Research Interests

Explore related searches

Contact this professor

Articles (10)

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL)

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies

Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma

Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma

Low mortality from COVID‐19 infection in patients with B‐cell lymphoma after bispecific CD20xCD3 therapy

Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation

Exploring new prognostic biomarkers in Mantle Cell Lymphoma

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors

Collaborators (5)

Judit Meszaros Joergensen

Sara Ek

Michael Boe Møller

Thomas Stauffer Larsen

Martin Hutchings

Make your next move.